Evaluating the role of statins in prevention of preeclampsia: deeper insights into maternal cardiometabolic changes.

[1]  Yen-Ju Chen,et al.  Perinatal Outcomes After Statin Exposure During Pregnancy , 2021, JAMA network open.

[2]  A. Sahebkar,et al.  A systematic review and meta-analysis on the effects of statins on pregnancy outcomes. , 2021, Atherosclerosis.

[3]  J. E. Roeters van Lennep,et al.  Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia. , 2021, Atherosclerosis.

[4]  S. Cicero,et al.  Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia , 2021, Circulation.

[5]  A. Sahebkar,et al.  Fetal toxicity associated with statins: A systematic review and meta-analysis. , 2021, Atherosclerosis.

[6]  R. Blumenthal,et al.  The Role of Biomarkers and Imaging to Predict Preeclampsia and Subsequent Cardiovascular Dysfunction , 2021, Current Treatment Options in Cardiovascular Medicine.

[7]  G. Saade,et al.  A Randomized Pilot Clinical Trial of Pravastatin Versus Placebo in Pregnant Patients at High-Risk of Preeclampsia. , 2021, American journal of obstetrics and gynecology.

[8]  K. Rexrode,et al.  Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association. , 2021, Circulation.

[9]  K. Giannakou,et al.  Pre‐eclampsia and long‐term health outcomes for mother and infant: an umbrella review , 2021, BJOG : an international journal of obstetrics and gynaecology.

[10]  C. Parker,et al.  Early Pregnancy Atherogenic Profile in a First Pregnancy and Hypertension Risk 2 to 7 Years After Delivery , 2021, Journal of the American Heart Association.

[11]  C. Silversides,et al.  The Importance of Cardiovascular Risk Assessment and Pregnancy Heart Team in the Management of Cardiovascular Disease in Pregnancy. , 2021, Cardiology clinics.

[12]  V. Mai,et al.  Treatment of Severe Hypertriglyceridemia During Pregnancy With High Doses of Omega-3 Fatty Acid and Plasmapheresis , 2021, AACE clinical case reports.

[13]  M. Costantine,et al.  The role of statins in the prevention of preeclampsia. , 2020, American journal of obstetrics and gynecology.

[14]  A. Stefanović,et al.  Lipid profile and lipid oxidative modification parameters in the first trimester of high- risk pregnancies - possibilities for preeclampsia prediction. , 2020, Clinical biochemistry.

[15]  Asif Ahmed,et al.  Pravastatin for early‐onset pre‐eclampsia: a randomised, blinded, placebo‐controlled trial , 2019, BJOG : an international journal of obstetrics and gynaecology.

[16]  E. Steegers,et al.  Is maternal lipid profile in early pregnancy associated with pregnancy complications and blood pressure in pregnancy and long term postpartum? , 2019, American journal of obstetrics and gynecology.

[17]  Daniel E Forman,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[18]  Wenzhen Li,et al.  Parity and risk of maternal cardiovascular disease: A dose–response meta-analysis of cohort studies , 2018, European journal of preventive cardiology.

[19]  Erkan Kalafat,et al.  Cardiovascular System in Preeclampsia and Beyond , 2019, Hypertension.

[20]  F. Raal,et al.  Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies. , 2018, Atherosclerosis.

[21]  Ming-Sum Lee,et al.  Statin exposure during first trimester of pregnancy is associated with fetal ventricular septal defect. , 2018, International journal of cardiology.

[22]  R. Charlton,et al.  Statins during pregnancy: a cohort study using the General Practice Research Database to investigate pregnancy loss , 2017, Pharmacoepidemiology and drug safety.

[23]  N. M. Yaacob,et al.  Increased circulating oxidised low-density lipoprotein and antibodies to oxidised low-density lipoprotein in preeclampsia , 2017, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[24]  Boxu Ren,et al.  The Role of HMGB1 in the Pathogenesis of Type 2 Diabetes , 2016, Journal of diabetes research.

[25]  G. Girardi,et al.  Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. , 2016, The Journal of clinical investigation.

[26]  Zhi-Wei Zhu,et al.  Associations between maternal lipid profile and pregnancy complications and perinatal outcomes: a population-based study from China , 2016, BMC Pregnancy and Childbirth.

[27]  S. Brennecke,et al.  Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. , 2016, The New England journal of medicine.

[28]  L. Brown,et al.  Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. , 2015, American journal of obstetrics and gynecology.

[29]  Meenakshi Singh,et al.  A Study on Atherogenic Indices of Pregnancy Induced Hypertension Patients as Compared to Normal Pregnant Women. , 2015, Journal of clinical and diagnostic research : JCDR.

[30]  P. Žák,et al.  Pregnancy in homozygous familial hypercholesterolemia--Importance of LDL-apheresis. , 2015, Atherosclerosis. Supplements.

[31]  S. Hernández-Díaz,et al.  Statins and congenital malformations: cohort study , 2015, BMJ : British Medical Journal.

[32]  M. Blaha,et al.  How do statins work?: changing paradigms with implications for statin allocation. , 2013, Journal of the American College of Cardiology.

[33]  A. Coomarasamy,et al.  Pre‐eclampsia is associated with, and preceded by, hypertriglyceridaemia: a meta‐analysis , 2013, BJOG : an international journal of obstetrics and gynaecology.

[34]  T. Buclin,et al.  Pregnancy outcome following maternal exposure to statins: a multicentre prospective study , 2013, BJOG : an international journal of obstetrics and gynaecology.

[35]  K. Cleary,et al.  Pravastatin for the Prevention of Preeclampsia in High-Risk Pregnant Women , 2013, Obstetrics and gynecology.

[36]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. , 2012, Lancet.

[37]  R. Hegele,et al.  Severe hypertriglyceridemia in pregnancy. , 2012, The Journal of clinical endocrinology and metabolism.

[38]  Asif Ahmed,et al.  Is inflammation the cause of pre-eclampsia? , 2011, Biochemical Society transactions.

[39]  P. Iversen,et al.  Pregnancy Outcomes in Familial Hypercholesterolemia: A Registry-Based Study , 2011, Circulation.

[40]  M. Ikawa,et al.  Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model , 2010, Proceedings of the National Academy of Sciences.

[41]  Asif Ahmed,et al.  Can the biology of VEGF and haem oxygenases help solve pre-eclampsia? , 2009, Biochemical Society transactions.

[42]  J. Kastelein,et al.  Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? , 2009, Current opinion in lipidology.

[43]  S. Haeri,et al.  Maternal serum dyslipidemia occurs early in pregnancy in women with mild but not severe preeclampsia. , 2008, American journal of obstetrics and gynecology.

[44]  B. Sibai,et al.  Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. , 2006, The New England journal of medicine.

[45]  A Metin Gülmezoglu,et al.  WHO analysis of causes of maternal death: a systematic review , 2006, The Lancet.

[46]  J. Ray,et al.  Brief overview of maternal triglycerides as a risk factor for pre‐eclampsia , 2006, BJOG : an international journal of obstetrics and gynaecology.

[47]  Jennifer G. Robinson,et al.  Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. , 2005, Journal of the American College of Cardiology.

[48]  I. Sargent,et al.  Latest Advances in Understanding Preeclampsia , 2005, Science.

[49]  K. Erdmann,et al.  The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. , 2004, Free radical biology & medicine.

[50]  V. Sukhatme,et al.  Angiogenic imbalance in the pathophysiology of preeclampsia: newer insights. , 2004, Seminars in nephrology.

[51]  M. Muenke,et al.  Central nervous system and limb anomalies in case reports of first-trimester statin exposure. , 2004, The New England journal of medicine.

[52]  K. Lim,et al.  Circulating angiogenic factors and the risk of preeclampsia. , 2004, The New England journal of medicine.

[53]  J. Liao,et al.  Endothelium-Dependent Effects of Statins , 2003 .

[54]  E. Herrera.  Lipid metabolism in pregnancy and its consequences in the fetus and newborn , 2002, Endocrine.

[55]  Kathleen M. Weil,et al.  Simvastatin Lowers C-Reactive Protein Within 14 Days: An Effect Independent of Low-Density Lipoprotein Cholesterol Reduction , 2002, Circulation.

[56]  J. Deisenhofer,et al.  Structural Mechanism for Statin Inhibition of HMG-CoA Reductase , 2001, Science.

[57]  F. Mach,et al.  Statins as a newly recognized type of immunomodulator , 2000, Nature Medicine.

[58]  N. Butte.  Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. , 2000, The American journal of clinical nutrition.

[59]  E. Herrera.  Metabolic adaptations in pregnancy and their implications for the availability of substrates to the fetus , 2000, European journal of clinical nutrition.

[60]  J Auwerx,et al.  Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.

[61]  M. Moskowitz,et al.  Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[62]  U. Laufs,et al.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.

[63]  G. Ness,et al.  Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. , 1996, Archives of biochemistry and biophysics.

[64]  M. Mitchell,et al.  Pre-eclampsia and serum antibodies to oxidised low-density lipoprotein , 1994, The Lancet.

[65]  D. Gómez-Coronado,et al.  Role of lipoprotein lipase activity on lipoprotein metabolism and the fate of circulating triglycerides in pregnancy. , 1988, American journal of obstetrics and gynecology.

[66]  T. Coltart,et al.  ADIPOSE TISSUE METABOLISM IN PREGNANCY: THE LIPOLYTIC EFFECT OF HUMAN PLACENTAL LACTOGEN , 1978, British journal of obstetrics and gynaecology.

[67]  FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins , 2021 .

[68]  L. Volpe,et al.  Triglyceride metabolism in pregnancy. , 2011, Advances in clinical chemistry.